



ASX Release
31st July 2019

Memphasys appoints corporate finance & capital markets executive to board

Australian-based bio-separations company Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) has appointed corporate finance and capital markets executive, Mr Shane Hartwig, as a Non-Executive Director of the Board, effective immediately.

Mr Hartwig is a Founder and Director of Peloton Advisory a well-established and highly successful corporate advisory firm with offices in Sydney and Perth.

He has over twenty years’ national and international experience in the finance industry with exposure to both the debt and equity capital markets. His experience covers Initial Public Offerings (IPO’s), capital raisings, prospectus and information memorandum preparation and project management, company assessments and due diligence reviews. Mr Hartwig also has extensive experience in mergers and acquisitions, including in takeover transactions.

Mr Hartwig, a Certified Practicing Accountant (CPA) and chartered Company Secretary, holds a Bachelor of Business degree, majoring in Accounting and Taxation from Curtin University of Technology in Western Australia.

Commenting on his appointment to the Board, Executive Chair, Alison Coutts said:

“Shane has a strong governance, corporate finance and corporate structuring background and vast experience in assisting emerging small cap companies through the listing and corporate development journey. We are fortunate to have such an experienced, high calibre executive on board.”

The Company recently announced the appointment of W&S Plastics Pty Ltd (“W&S”), one of the largest custom plastic injection moulding companies in Australia to manufacture and assemble its Felix disposable cartridges (refer ASX announcement dated 9 July 2019). Simultaneously, it also confirmed a \$4.2 million Placement to facilitate the modified tooling strategy and ensure the business is suitably funded into first commercial sales.

Memphasys is on track to meet its commercialisation timeline for the Felix device (refer ASX release of 9 April 2019). Subject to the receipt of required regulatory approvals on or before Q2 2020, Memphasys plans to be in a position to launch its sales program for the Felix device in Q2 2020.

ENDS

For further information please contact:

Alison Coutts
Executive Chairman
Memphasys Limited
T: +61 2 8415 7300
E: alison.coutts@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
T: +0433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained. The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.